MedPath

Investigation of interavenous Ketamine anti depressant effects on major depressive disorder patients

Phase 4
Conditions
Major depressive disorder.
Severe depressive episode without psychotic symptoms
Registration Number
IRCT2015030921072N2
Lead Sponsor
Babol University of Medical Sciences, Research Deputy
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
100
Inclusion Criteria

Patients with major depressive disorder according to DSM-V criteria with different severity and with out psychotic feature were selected.this patient also lacks a somatoform disorder and personality disorder co-morbidity, hypertension and heart disease and over the last month are not under medical treatment.

Exclusion Criteria

Not provided

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Depression. Timepoint: Pre intervension, 2, 7, 30, 60 dayes post intervension. Method of measurement: Hamilton and Beck test.
Secondary Outcome Measures
NameTimeMethod
Drug dose. Timepoint: Pre intervension, 2, 7, 30, 60 dayes post intervension. Method of measurement: Hamilton and Beck test.;Method Of Injection. Timepoint: Pre intervension, 2, 7, 30, 60 dayes post intervension. Method of measurement: Hamilton and Beck test.
© Copyright 2025. All Rights Reserved by MedPath